Licence Agreement in HTS Stroke

28 June 2006

Proteome Sciences plc ("Proteome Sciences") is pleased to announce a licence agreement with one of the top 10 global leaders in clinical diagnostics to use its biomarkers for the detection, diagnosis and monitoring of stroke. This is a new area for the licencee who has determined not to disclose its identity at this time for competitive reasons. The biomarkers were discovered and validated using a combination of different proteomic approaches available for external use through the proprietary ProteoSHOP® platform.

Stroke is the brain equivalent of a heart attack. Blood must flow in and through the brain for it to function. If its flow is obstructed by a blood clot moving to the brain or by narrowing or blocking of blood vessels, the brain loses its energy supply, causing damage to tissues leading to stroke.

Annually, 15 million people worldwide suffer a stroke. Of these, 5.5 million die and another 5 million are left permanently disabled, placing a burden on family and community.

Stroke is the third leading cause of death in the US (160,000 deaths) with annual costs of $57.9bn for stroke-medical related costs and disability and the single most common cause of severe disability. 750,000 people are diagnosed in the US annually having new or recent strokes.

Under the research licence, a number of Proteome Sciences biomarkers will be tested in stroke for inclusion on a new panel for the licencee's high-throughput diagnostic platforms. No financial details were disclosed.

The preliminary announcement of Proteome Sciences results for the year ended 31st December, 2005 will be released by 30th June, 2006.

Christopher Pearce, CEO of Proteome Sciences, said:

"This licencee is world renowned in clinical diagnostics and has built a strong customer base ideally placed to introduce and support new stroke diagnostic products globally. This reflects their commitment to develop innovative assays and solutions to address the major unmet diagnostic and prognostic needs in stroke.

They have been impressed by Proteome Sciences' ProteoSHOP® technology to discover novel biomarkers in blood and to progress these rapidly for the market place. This agreement brings important new biomarkers to their IVD pipeline and the opportunity to diagnose stroke in a high- throughput system. We look forward to incorporation of our stroke markers onto their systems and to a rapid introduction of an HTS stroke test."